14 research outputs found
Marked increase of procalcitonin after the administration of anti-thymocyte globulin in patients before hematopoietic stem cell transplantation does not indicate sepsis: a prospective study
W1212 Anti-Infliximab Antibodies in Routine Clinical Practice - Is It Worth to Assess Them?
202 Decreased Activity of DNase-I Predisposes to Immune-Mediated Complications in IBD Patients During Anti-TNFA Treatment
W1906 Skin Complications During Therapy With Anti-TNFα Preparations: Experience of a Single Centre
Tu1175 Risk Factors of Crohn's Disease Exacerbation After Termination of Anti-TNF Alpha Therapy in Remission: A Prospective, Single Center Trial
The production of mannan-binding lectin is dependent upon thyroid hormones regardless of the genotype : a cohort study of 95 patients with autoimmune thyroid disorders
Complement mannan-binding lectin (MBL) deficiency is associated with increased susceptibility to infections and autoimmune diseases. Previous studies suggested that the production of MBL is stimulated by thyroid hormones. The aim of our study was to investigate this association in patients with autoimmune thyroid diseases (AITD). Serum levels of MBL and parameters of the thyroid function were determined in 62 patients with Hashimoto's thyroiditis, 33 with Graves' disease and 47 blood donors. Follow-up measurements were performed after 6 to 24 months. MBL2 genotypes were determined using multiplex PCR and compared to 359 healthy Czech individuals. Serum levels of MBL tightly correlated with thyroid hormones, leading to strongly increased MBL levels in hyperthyroidism and decreased levels in hypothyroidism. With normalization of the thyroid function during follow-up, MBL levels decreased or increased respectively. The observed correlations were not due to MBL polymorphisms since the frequency of MBL2 polymorphisms in AITD patients was not different from the general population. We conclude that AITD are not associated with MBL polymorphisms. However, the MBL production is strongly dependent on thyroid function, regardless of the genotype
Mo1919 – Ustekinumab Efficiency As a Higher-Line Therapy in Association with Serum Levels in Patients with Crohn’s Disease
Mo1894 – Early Vedolizumab Trough Levels are Not Associated with a Short-Term Response in Patients with Inflammatory Bowel Disease
Sa1698 - Impact of Anti-Tnfa Exposure During Pregnancy for Maternal Inflammatory Bowel Disease on Serologic Response to Vaccination of Exposed Children
Infliximab biosimilar CT-P13 therapy is effective in maintaining endoscopic remission in ulcerative colitis - results from multicenter observational cohort
Background: CT-P13, the first biosimilar monoclonal antibody to infliximab (IFX), has previously been confirmed to be efficacious in inducing mucosal healing in ulcerative colitis (UC) patients. The aim of this study was to evaluate the efficacy of CT-P13 therapy in maintaining mucosal healing in UC. Methods: CT-P13 trough levels, antibody positivity, serum inflammatory markers as CRP level, fecal calprotectin at weeks 14 and 54, concomitant steroid and azathioprine therapy at the time of induction therapy and at weeks 14 and 54, previous use of anti TNF drug and the need of dose intensification as possible predictive factors for mucosal healing at week 54 were evaluated in this prospective study. Results: 61 patients had already completed the 54-week treatment period. Mucosal healing was shown in 65.5 % and 62.1 %, complete mucosal healing was present in 31% and 38 % at week 14 and 54, respectively. The median values of CRP, leukocytes, thrombocytes, and albumin showed significant difference between baseline and week 54. Serum antibody positivity was proved in 6.5 % and 19.7 % of cases at week 14 and 54, respectively. Conclusion: Our study confirmed the long-term efficacy of CT-P13 therapy on mucosal healing in UC